Lead Product(s) : Orziloben
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NorthSea Initiates Phase 2A of Orziloben in Intestinal Failure-Associated Liver Disease
Details : NST-6179 (orziloben) is a novel, orally administered, highly potent, synthetic, medium chain fatty acid analogue. It is being evaluated for treating intestinal failure-associated liver disease.
Product Name : NST-6179
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2024
Lead Product(s) : Orziloben
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable